Cardiometabolic risk variables in overweight and obese children: a worldwide comparison

Mariska van Vliet1, Martijn W Heymans, Inès A von Rosenstiel

  • 1Department of Pediatrics, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands. Mariskavv@hotmail.com

Cardiovascular Diabetology
|November 26, 2011
PubMed

Insights

Pediatric obesity is a global concern. This review found significant international variations in cardiometabolic risk factors among overweight children, highlighting differing health profiles worldwide.

Area of Science:

  • Pediatric Endocrinology
  • Global Public Health
  • Cardiovascular Health

Background:

  • Pediatric obesity rates are rising globally, often linked to cardiometabolic risk factors.
  • Understanding international disparities in these risk factors among children is crucial.

Purpose of the Study:

  • To review and compare cardiometabolic risk factors in overweight pediatric populations across different countries.
  • To analyze prevalence and mean values of key metabolic syndrome components.

Main Methods:

  • Systematic review of existing literature on overweight children.
  • Selection of comparable cohorts based on age and sex.
  • Comparison of prevalence and mean values for impaired glucose, high triglycerides, low HDL-cholesterol, and hypertension.

Main Results:

  • Significant variations in cardiometabolic risk factor prevalence and means were observed among international cohorts.
  • Children from Turkey, Hungary, Greece, Germany, Poland, and Dutch-Turkish populations showed the least favorable risk profiles.
  • Children from Norway, Japan, Belgium, France, and the Dominican Republic exhibited the most favorable risk profiles.

Conclusions:

  • There are substantial global differences in cardiometabolic risk profiles among overweight children.
  • Findings should be interpreted cautiously due to cohort heterogeneity and limited outcome data.
  • This review provides an estimation of international disparities in pediatric cardiometabolic risk.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...